Poly Medicure Limited

NSEI:POLYMED Stok Raporu

Piyasa değeri: ₹236.2b

Poly Medicure Yönetim

Yönetim kriter kontrolleri 2/4

Poly Medicure CEO'su Himanshu Baid, Sep1995 tarihinde atandı, in görev süresi 29.33 yıldır. in toplam yıllık tazminatı ₹ 171.78M olup, şirket hissesi ve opsiyonları dahil olmak üzere 33.6% maaş ve 66.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 11.59% ine doğrudan sahiptir ve bu hisseler ₹ 27.38B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.6 yıl ve 6.7 yıldır.

Anahtar bilgiler

Himanshu Baid

İcra Kurulu Başkanı

₹171.8m

Toplam tazminat

CEO maaş yüzdesi33.6%
CEO görev süresi29.3yrs
CEO sahipliği11.6%
Yönetim ortalama görev süresi6.6yrs
Yönetim Kurulu ortalama görev süresi6.7yrs

Son yönetim güncellemeleri

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Recent updates

Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Jan 28
Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06
After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14
Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11
Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23
Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15
Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24
Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08
Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16
Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02
Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16
Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08
Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07
A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23
Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04
There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

CEO Tazminat Analizi

Himanshu Baid'un ücretlendirmesi Poly Medicure'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹172m₹58m

₹3b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹130m₹55m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹1b

Jun 30 2022n/an/a

₹1b

Mar 31 2022₹107m₹49m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹92m₹44m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹62m₹35m

₹959m

Dec 31 2019n/an/a

₹947m

Sep 30 2019n/an/a

₹858m

Jun 30 2019n/an/a

₹719m

Mar 31 2019₹44m₹14m

₹654m

Mar 31 2018₹41m₹14m

₹706m

Tazminat ve Piyasa: Himanshu 'nin toplam tazminatı ($USD 1.98M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 572.63K ).

Tazminat ve Kazançlar: Himanshu 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Himanshu Baid (56 yo)

29.3yrs

Görev süresi

₹171,781,000

Tazminat

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Himanshu Baid
CEO, MD & Director29.3yrs₹171.78m11.59%
₹ 27.4b
Jugal Baid
Founder & Non Executive Directorno data₹1.43m2.25%
₹ 5.3b
Naresh Vijayvergiya
Chief Financial Officer3.5yrs₹11.21mVeri yok
Avinash Chandra
Company Secretary & Compliance Officer9.7yrs₹1.88mVeri yok
Rishi Baid
Joint MD & Executive Directorno data₹166.82m12.33%
₹ 29.1b
Vishal Baid
President of Corporate Sales & Marketing2.8yrs₹18.39m1.66%
₹ 3.9b
P. Rastogi
Assistant Vice President of Finance & Accountsno dataVeri yokVeri yok
Hemant Bhalla
Senior Vice President of Domestic Sales & Marketingno data₹5.79mVeri yok
Pankaj Gupta
President of R&Dno data₹5.61mVeri yok
Manish Sardana
President of Sales & Marketing - Indiano data₹8.61mVeri yok

6.6yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: POLYMED 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Himanshu Baid
CEO, MD & Director29.8yrs₹171.78m11.59%
₹ 27.4b
Jugal Baid
Founder & Non Executive Director29.8yrs₹1.43m2.25%
₹ 5.3b
Rishi Baid
Joint MD & Executive Director29.8yrs₹166.82m12.33%
₹ 29.1b
Vimal Bhandari
Non-Executive Independent Directorless than a yearVeri yokVeri yok
Amit Khosla
Non-Executive Independent Director4.6yrs₹1.60mVeri yok
Vishal Gupta
Independent Directorno dataVeri yokVeri yok
Devendra Mehta
Non-Executive Independent Chairman19.7yrs₹1.63mVeri yok
Mukulika Baid
Non-Executive Director10.5yrs₹1.43m3.02%
₹ 7.1b
Sonal Mattoo
Non-Executive Independent Director4.4yrs₹1.45mVeri yok
Alessandro Balboni
Non-Executive Non Independent Director6.7yrs₹29.90mVeri yok
Ambrish Mithal
Independent Director2.8yrs₹1.45mVeri yok

6.7yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: POLYMED 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/01/31 10:11
Gün Sonu Hisse Fiyatı2025/01/31 00:00
Kazançlar2024/09/30
Yıllık Kazançlar2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Poly Medicure Limited 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Nitin BhasinAmbit Capital
Karan KhannaAmbit Capital
Sunita VaidyanathanBrics Securities Limited